247 related articles for article (PubMed ID: 16874697)
1. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
2. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
Portolés J; López-Gómez JM; Aljama P
Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
[TBL] [Abstract][Full Text] [Related]
3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.
Portolés J; López-Gómez JM; Aljama P
Nephrol Dial Transplant; 2007 Feb; 22(2):500-7. PubMed ID: 17023492
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
6. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
7. Individualizing anaemia treatment: a discussion of case histories.
Muirhead N
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
9. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
[TBL] [Abstract][Full Text] [Related]
10. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
14. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value].
Wallerstedt SM; Ljungman S; Broms E; Andrén L
Lakartidningen; 2005 Sep 12-18; 102(37):2550-1, 2553-5. PubMed ID: 16200900
[TBL] [Abstract][Full Text] [Related]
15. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
[TBL] [Abstract][Full Text] [Related]
16. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
Macdougall IC; Temple RM; Kwan JT
Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
18. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
[TBL] [Abstract][Full Text] [Related]
19. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
[TBL] [Abstract][Full Text] [Related]
20. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
